Bristol Myers Squibb

Historical price data

Bristol Myers Squibb (BMS) is a premier global biopharmaceutical company with a mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. The company has achieved landmark status through transformative therapies like Opdivo (nivolumab) and Yervoy in immuno-oncology, and maintains a robust pipeline fueled by a strategy of causal human biology and modality matching. BMS's core strategy involves a disciplined R&D framework, strategic business development to bolster its pipeline, and a focus on expanding the reach of its cell therapy and novel oncology assets while navigating near-term patent expirations.

A multi-modal platform integrating cell therapy, targeted protein degradation (CELMoDs), radiopharmaceuticals, antibody-drug conjugates (ADCs), and advanced biologics/small molecules, guided by a research strategy rooted in causal human biology and modality matching.

BMS competes fiercely with large pharma peers like Merck, Roche, and Johnson & Johnson in oncology and immunology, and with biotech innovators in cell therapy. Its differentiation stems from an integrated multi-modal platform, deep scientific expertise in areas like protein degradation, and a proven ability to execute large-scale commercial launches and strategic acquisitions.